Abbott's atrasentan meets CKD endpoint

Abbott Laboratories (NYSE:ABT) said two of three doses of once-daily atrasentan for eight weeks met the primary endpoint vs. placebo in a Phase II trial to treat chronic kidney disease (CKD) in patients with Type II diabetes. The 0.75 and 1.75 mg doses of the endothelin A receptor antagonist significantly reduced mean urinary albumin-to-creatinine ratio (UACR) from baseline to each weekly measurement vs. placebo (p=0.001 and p=0.011, respectively). The 0.25 mg dose missed the endpoint. Low-, mid- and high-dose atrasentan reduced UACR from baseline to week eight by 21%, 42% and 34%, respectively, vs. 11% for placebo (p=0.292, p=0.023 and p=0.08, respectively). ...